Louis Lacombe
Université Laval
H-index: 66
North America-Canada
Top articles of Louis Lacombe
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression
The Journal of Clinical Investigation
2024/4/16
Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada
Human Pathology
2024/4/10
A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation
Communications Medicine
2024/3/22
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC
Canadian Urological Association Journal
2024/2
11-Ketotestosterone and time to castration resistance in patients with recurrent non-metastatic prostate cancer receiving androgen deprivation therapy.
2024/2/1
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
2024/2/1
Effects of omega‐3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double‐blind placebo‐controlled randomized trial
Cancer Medicine
2023/10
Pierre Julien
H-Index: 27
Louis Lacombe
H-Index: 45
Paul Toren
H-Index: 15
Michele Lodde
H-Index: 18
Yves Fradet
H-Index: 44
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer
Molecular Oncology
2023/10
Alain Bergeron
H-Index: 37
Yves Fradet
H-Index: 44
Louis Lacombe
H-Index: 45
Michael Shum
H-Index: 8
Martin Pelletier
H-Index: 20
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
The Lancet Oncology
2023/8/1
High infiltration of CD209+ dendritic cells and CD163+ macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes
Frontiers in Immunology
2023/6/26
Bernard Têtu
H-Index: 47
Louis Lacombe
H-Index: 45
Paul Toren
H-Index: 15
Alain Bergeron
H-Index: 37
Yves Fradet
H-Index: 44
First-line lenvatinib+ pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.
2023/6/1
Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study
Cancers
2023/4/9
Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation on quality of life after radical prostatectomy: a phase II randomized placebo-controlled …
Nutrients
2023/3/11
Preoperative circulating 11-oxygenated androgens are associated with metastasis-free survival in localized prostate cancer
The Journal of Urology
2023/2
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways
Cancer Letters
2023/1/28
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer
British Journal of Cancer
2023/1/19
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians’ perspective
Canadian Urological Association Journal
2022/10
Yves Fradet
H-Index: 44
Louis Lacombe
H-Index: 45
Katherine Moore
H-Index: 2
Paul Toren
H-Index: 15
Michele Lodde
H-Index: 18
1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro)+ lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
Annals of Oncology
2022/9/1
1418P Extensive alteration of androgen precursor levels after castration in prostate cancer patients and their association with active androgen level: Importance for treatment …
2022/9/1
Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion
Molecular Metabolism
2022/8/1
Alain Bergeron
H-Index: 37
Yves Fradet
H-Index: 44
Louis Lacombe
H-Index: 45
Isabelle Laverdière
H-Index: 10
